REFERENCES

1. Srinivas NR (2008), Changing need for bioanalysis during drug development; Biomedical Chromatography; 22(3):235-43.
2. Pandey S et al. (2010), Bioanalysis in drug discovery development; Pharmaceutical methods, Vol.1:14-24.
3. Viswanathan CT et al. (2007), Workshop/Conference report- Quantitative bioanalytical methods validations and implementation: Best practices for chromatographic and ligand binding assays; The AAPS Journal; 9(1) Article 4.
4. Viswanathan CT et al. (2007), Quantitative Bioanalytical Methods Validation and Implementation Best practices for Chromatographic and Ligand binding Assay; Pharmaceutical research, Vol 24; (10), 1962.
5. Naxing RX et al. (2007), recent advances in high throughput quantitative bioanalysis by LC-MS/MS; Journal of Pharmaceutical and biomedical analysis Vol 44, Issue 2, 342-355.
6. Zhou M (2011), Regulated Bioanalytical Laboratories: Technical and regulatory aspects from Global perspectives pg. 229.
7. Wang LZ et al. (2009), Rapid determination of Gemcitabine and its metabolite in human plasma by LC-MS/MS through micro protein precipitation with minimum matrix effect; Journal of Pharmaceutical Science and research, Vol 1(3),2009, 23-32.
8. Hefnawy MM (2002), Analysis of certain tranquilizers in biological fluid; Journal of Pharmaceutical and biomedical analysis Vol 27, Issue 5,661-678.
9. Nair A et al. (2010), Quantitative bioanalysis by LC-MS/MS: A review; Journal of Pharmaceutical and biomedical sciences, Vol 7, Issue 7, 01-07.
10. Mike S Lee and Edward H Kerns (1999); LC/MS Applications in drug development, Mass spectrometry Reviews, 18, 187-279.
11. A guide to effective method development in bioanalysis (2008), published by Waters Corporation USA, http://www.waters.com/webassets/cms/library/docs/720002710en.pdf.
12. Patil VP et al. (2011), Ultra performance liquid chromatography: A review; International Research journal of Pharmacy 2(6), 39-44.
13. Rainville P D (Feb 2010), Addressing the issues of very sharp LC peaks width in quantitative LCMS/MS; Chromatography Today, 12-14.
14. Guidance for Industry: Bioanalytical Method Validation, CDER, May 2001, BP.
15. Shah VP (2007), The history of bioanalytical method validation and regulation: Evolution of a guidance document on bioanalytical methods validation; The AAPS journal 9(1): Article 5.

16. Hopfgartner G et al.(2004), Triple Quadrupole linear ion trap mass spectrometer for analysis of small molecules and macro molecules; Journal of Mass Spectrometer 39:845-855.
17. Chambers E et al. (2007), Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses; Journal of chromatography B, 852; 22-34.
18. Mannur VS et al. (Feb 2011), Selection of buffers in LC-MS/MS: An overview; International journal of Pharmaceutical Sciences review and research, Vol 6; Issue 1, Article 8.
19. Want E et al. (2003), the application of Mass spectrometry in Pharmacokinetic studies; Spectroscopy 17, 681-691.
20. Bocxlaer JFV et al. (2000), Liquid chromatography-Mass Spectrometry in Forensic Toxicology; Mass Spectrometry Reviews; 19, 165-214.
21. Sakai-Kato K et al.(2010), Analysis of intracellular doxorubicin and its metabolites by ultra-high-performance liquid chromatography, Journal of Chromatography; Vol 878, Issue 19, 1466-1470.
22. Ch.Krishnaiah et al. (2010), Stability indicating UPLC method for valsartan and its degradation products in active pharmaceutical ingredient and pharmaceutical dosage form; Journal of Pharmaceutical and biomedical Analysis, Vol 53, Issue 3, 483-489.
23. Gaikwad PV et al. (2010), Ultra performance liquid chromatography: A recent novel development in HPLC; Pharmacie Globale (IJCP); Vol 1, Issue 2: 1-8.
24. Swartz ME (2004), Ultra performance liquid chromatography: Tomorrow's HPLC technology today; LabPlus International.; 18(3): 6-9.
25. Taylor PJ (2005), Matrix effect: The Achilles heel of Quantitative high performance liquid chromatography electrospray-tandem mass spectrometry; Clinical Biochemistry 38: 328-334.
26. Patel K et al. (2010), A review of the role of monolithic phases in bio-analysis with special emphasize on separation and sample pre-treatment; International Journal of Pharmaceutical and Applied Sciences1(1) 29-43.
27. Kole PL et al. (2011), Recent Advances in sample preparation techniques for effective bioanalytical methods; Biomedical chromatography; 25: 199-217.
28. Wal P et al. (2010), Bioanalytical method development- determination of drugs in biological fluids; Journal of Pharmaceutical Science and Technology, Vol 2(10), 333-347.
29. Immrie G A et al. (2009), Bioanalysis by LC-MS some pragmatic solutions to common occurring problems, Chromatography Today, June 2009, 27-30.

30. Reddy BH et al. (2010), Ultra Performance Liquid Chromatography: A Review; Journal of Innovative trends in Pharmaceutical Sciences, Vol 1(3):115-132.
31. May L. Chiu et al. (2010), Matrix Effect: A challenge towards automation of molecular analysis; Journal of Laboratory automation 15:233.
32. Cappiello A et al. (2008), Overcoming Matrix effect in Liquid-Chromatography Mass spectrometry; Analytical Chemistry, 80:9343-9348
33. Jadhav D H et al. (2012), Development and Validation of a UPLC-MS/MS Assay for Simultaneous Estimation of Raloxifene and its Metabolites in Human Plasma; Journal of Bioanalysis and biomedicine, Vol 4(4):61-67.
34. Dujuan Zhang et al. (2011), Validated LC-MS/MS method for determination of Rosuvastatin in human plasma: Application to Bioequivalence study in Chinese volunteers; Pharmcology and Pharmacy 2:341-346.
35. Marlus Chorilli et al. (2011), Development and Validation of LC-MS/MS method for Quantitative Analysis of Mirtazapine in human plasma; American journal of Analytical Chemistry 2,650-657.
36. Rama Rao K et al. (2009), Bioanalytical Method Validation:A Quality Assurance Auditor View point; Journal of pharmaceutical science and researchVol 1(3)1-10.
37. Dharmendra Patel (2010), Matrix Effect In a view of LC-MS/MS : An overview; International Journal of Pharma and Biosciences, Vol 2, Issue 1, 559-564.
38. D Chnadrapal reddy et al. (2012), Development and Validation of a LC/MS/MS Method for the Determination of Duloxetine in Human Plasma and Its Application to Pharmacokinetic Study; Journal of Chemistry Vol 9(2), 899-911.
39. Mathew Ewles et al. Global bioanalytical Services white paper. http://resource.covance.com/pdf/wpbio001-1110spdf.pdf
40. Armin Buchwald et al. (2012), Validation of an LC-MS/MS method to determine five immunosuppressants with deuterated internal standards including MPA; Clinical Pharmacology 12:2.
41. Shafeeque Ahmed et al. (2012), Hybrid SPE: A novel technique to reduce phospholipid based matrix effect in LC-ESI-MS bioanalysis; Journal of Pharmacy and Bioallied Sciences Vol 4(4) 267-275.

42. Douglas M Fast et.al.(2009), Workshop report and follow up- AAPS workshop on current topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples-Implications of Crystal City Recommendations; The AAPS Journal Vol 11(2): 238-241.